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Purpose: To develop and validate a dissolution test method for dissolution release of artemether and 
lumefantrine  from tablets. 
Methods: A single dissolution method for evaluating the in vitro release of artemether and lumefantrine 
from tablets was developed and validated. The method comprised of a dissolution medium of 1000 ml of 
2 %w/v of Myrj 52  in 0.005M HCl per vessel with the paddle rotating at 100 rpm for 120 min. The 
dissolution samples were analysed using a Waters HPLC system with Waters symmetry column (C-18 
column of 250mm x 4.6mm i.d., 5 µ particle size). The mobile phase was a mixture of 20 volumes of 0.5 
%v/v of triethylamine in water (adjusted to a pH of 3.0 with orthophosphoric acid) and 80 volumes of 
acetonitrile. The detection wavelength was set at 216 nm and 100 µl of each sample was injected. The 
HPLC method used for the determination of drug release was validated for the parameters of accuracy, 
precision, linearity, specificity, filter validation, solution stability and robustness.  
Results: The dissolution test provided sink conditions for artemether and lumefantrine and was able to 
discriminate between tablet formulations of different hardness and different composition. Application of 
Mann-Whitney U test for significant difference between samples at various time points during the 
dissolution test yielded z values > 1.96 (1.96 = critical z value at p = 0.05)  for the various formulations 
tested, indicating the discriminatory power of the dissolution test.  
Conclusion: This validated dissolution test may be used as a single dissolution test for artemether and 
luminfantrine in tablet formulations. 
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INTRODUCTION 
 
Artemether is a drug used for the treatment of 
malaria [1,2]. Artemether and lumefantrine 
combination is a fixed dose artemisinin-based 
combination therapy (ACT) combining 
artemether, an artemisinin derivative, and 
lumefantrine, a synthetic antimalarial drug for 
the treatment of malaria [3,4]. Artemether is a 
fast acting drug with a short half-life. 
Lumefantrine acts slowly and has a longer 
half-life. On oral administration, the plasma 
concentration of artemether reaches peak 
level after 2 h while the peak plasma 
concentration of lumefantrine is attained after 
6 - 8 h [ 5 ]. 
 
The International Pharmacopoeia monograph 
of artemether and lumefantrine tablet does 
not include a dissolution test [6]. No common 
single dissolution test method for 
simultaneous dissolution testing of 
artemether and lumefantrine tablets has been 
reported in the literature although separate 
dissolution methods for artemether and 
lumefantrine have been developed [7].  
Artemether is poorly soluble in water while 
lumefantrine is practically insoluble in water. 
In general, developing an appropriate single 
dissolution method of discriminatory nature to 
evaluate the dissolution release of poorly 
soluble drugs from dosage forms has been a 
lingering challenge. [8-11] 
 
In the present study, a single dissolution test 
method for the dissolution release of 
artemether and lumefantrine which will be 
very useful for quality control of combination 
tablets has been designed and validated in 
terms of the discriminatory power of the 
dissolution test. The HPLC method used for 




Reagents and materials 
 
The working standards of artemether (99.4 % 
purity) and lumefantrine (98.3 % purity) were 
obtained from Micro Labs Ltd, India. Three 
reference products (A, B and C), each 
containing 20 mg of artemether and 120 mg 
of lumefantrine were obtained from Indian 
market. The test tablet product used was 
manufactured in-house. Water purified with 
Millipore Water Purification System (Elix 10 C 
model) was used for the preparation of 
buffers. Sodium acetate trihydrate, glacial 
acetic acid AR, potassium dihydrogen 
phosphate and sodium hydroxide pellets 
were sourced from Merck, India. PTFE 
membrane filters (0.45 µ, syringe filter – 
25mm GD/X- Whatman) were used for 
filtration of standard and sample solutions. 
Cellulose acetate filter (0.45 µ, Sartorium 
stedim) was used for the filtration of the 




The dissolution test was carried out using an 
Electrolab Dissolution Test System (Model 
TDT-08L). A Waters HPLC system equipped 
with a 2695 solvent delivery system, Waters 
auto injector, thermostatted column 
compartment and Waters 2998 photo diode 
array detector was used.  Waters Symmetry 
column (C-18 column of 250mm x 4.6mm i.d., 
5 µ particle size) was used for the analysis.  
 
Determination of solubility of artemether 
and lumefantrine 
 
The solubility of artemether and lumefantrine 
was determined in the various dissolution 
media as follows. Artemether (500 mg) and 
lumefantrine (500 mg) were transferred into 
separate 100 ml conical flasks.  Dissolution 
medium (50 ml) was added to each flask and 
the flasks were closed with Teflon-lined 
screw caps. These flasks were sonicated for 
2 h at 37 °C with intermittent shaking. The 
solutions were each filtered, through a 0.45 µ 
Whatman membrane filter. Each filtrate was 
analysed separately by HPLC to determine 
the solubility of the drug in the particular 
dissolution medium.  
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Evaluation of stability of the drug 
solutions 
 
The stability of artemether and lumefantrine 
in different dissolution media was evaluated 
at room temperature by calculating the 
change in peak area of samples at different 
time points which was then compared with 
that of the same sample immediately after 
injection.  
 
Stirring rate and dissolution medium 
 
Dissolution experiments were performed 
using standard USP dissolution apparatus 1 
(basket) and apparatus 2 (paddle). Stirring 
rates of 100 rpm for basket, and 50, 75 and 
100 rpm for paddle were evaluated. All the 
dissolution media used were de-aerated by 
sonication followed by filtration using 
membrane filter under vacuum.  
 
Sample preparation and determination  
 
The dissolution test was carried out using 1, 
1.5 and 2 %w/v of Myrj 52 (polyoxyl 40  
stearate) in 0.005M hydrochloric acid.  
Sample aliquots of 5.0 ml were withdrawn at 
different time points up to 120 min. After each 
withdrawal, a volume of dissolution medium 
equal to the volume of sample withdrawn was 
added to each vessel to maintain the volume 
in each vessel. The samples were filtered 
and analysed by HPLC and the percent drug 
release at each dissolution time point 
calculated. 
 
Selection of sample filtration procedure 
 
The filtration procedure for standard and 
sample solutions was evaluated using 2.5 µ 
pore filter paper (Whatman), 0.45 µ PTFE 
syringe filter (Whatman) and 0.45 µ nylon 




The discriminatory power of the dissolution 
test was evaluated by (a) comparison of the 
dissolution results of reference products A, B, 
C and in-house test product (b) comparison 
of the dissolution results of in-house test 
product of various hardness (c) comparison 
of test results of the test products stored at 
40 ºC and 75% RH with those of the test 
products stored at room temperature and 




The dissolution samples were analysed using 
Waters HPLC system, Symmetry column (C-
18 column of 250mm x 4.6mm i.d., 5 µ 
particle size) with a mobile phase of a mixture 
of buffer and acetonitrile (20:80, v/v) at a flow 
rate of 1.0 ml/min. The buffer for mobile 
phase was prepared by diluting 5 ml of 
triethylamine to 1000 ml with water and 
adjusting the pH to 3.0 ± 0.05 using 
orthophosphoric acid. The detection 
wavelength was set at 216 nm and 100 µl of 
each sample was injected.   
 
Preparation of lumefantrine standard 
stock solution 
 
About 240 mg of lumefantrine working 
standard was accurately weighed and 
transferred into a 100 ml volumetric flask. 
About 25 ml of mobile phase and one drop of 
orthophosphoric acid were added, the 
solution sonicated to dissolve the drug and 
the volume made up to 100 ml with mobile 
phase.   
 
Artemether standard stock solution 
 
About 20 mg of artemether working standard 
was accurately weighed and transferred into 
a 100 ml volumetric flask. About 5 ml of 
acetonitrile was added and the solution was 
sonicated to dissolve the substance; the 





Lumefantrine standard stock solution (5 ml) 
and 10 ml of artemether standard stock 
solution were transferred into a 100 ml 
volumetric flask and made up to volume with 
dissolution medium to obtain a concentration 
of 120 µg of lumefantrine and 20 µg of 
artemether per ml. This solution was filtered 
through 0.45 µ PTFE membrane filter 
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During the dissolution test, 5 ml aliquots were 
withdrawn from the dissolution medium at 
various time points up to 120 min and 
replaced with an equal volume of fresh 
dissolution medium after each withdrawal  to 
maintain a constant volume of the dissolution 
medium in the vessel. The samples were 
filtered through 0.45 µ PTFE membrane filter 
(Whatman) and the filtrate used as sample 
solution.  
 
System suitability parameters 
 
System suitability parameters of not less than 
5.0 resolution between artemether and 
lumefantrine peaks, not more than 2.0 tailing 
factor for each peak, not less than 2000 
theoretical plates for each peak and a %RSD 
of not more than 2.0 for five replicates of 
standard injection were specified as the 
system suitability requirements for the 




The HPLC method was validated for 
specificity, linearity, precision, accuracy, filter 
validation, solution stability and robustness 




The dissolution values of the various 
formulations at different time points were 
compared using similarity factor (f2) and 
difference factor (f1) which were calculated 




 (Rt - Tt )] / [∑t =1
n 
Rt]} x 100 ………… (1) 
 
f2=50x log {[1+ (1/n)∑t =1
n ( Rt - Tt )
2] -0.5  x 100} ..... (2) 
 
where Rt and Tt are the cumulative 
percentage dissolved at each of the selected 
‘n’ time points of the reference and test 
product respectively 
 
The calculation was performed with Microsoft 
Office Excel 2003. The difference between 
the dissolution values of various formulations 
was evaluated using Mann-Whitney U test 
and the calculated z values were compared 
with the critical z value of 1.96 (p = 0.05). 
This calculation was carried out using a web 
calculator [14]. The %RSD value and the 
linear regression analysis by the method of 





The solubility and stability data for artemether 
and lumefantrine in various commonly used 
dissolution media are presented in Tables 1 
and 2 on the basis of which the most suitable 
dissolution medium was selected.  
 
The dissolution values of reference product A 
in 0.005M HCl containing 1.0, 1.5  and 2.0% 
w/v of Myrj 52 are presented in Table 3 while 
those of the reference products A, B, C and 
the test product in the selected dissolution 
medium of 2% w/v Myrj 52  in 0.005N 
hydrochloric acid at various time points are 
presented in Table 4. The dissolution results 
of a formulation at a particular time point 
were different from those of other 
formulations at the same time point as per 
the Mann-Whitney U test.  The difference 
factor (f1) values for the various formulations 
indicate significant difference in the release 
pattern of the formulations when compared 
with reference product A. 
 
Validation of the HPLC method  
 
The validation results for the HPLC method 
used for the determination of drug release 




The accuracy of the method in the range of 
25 to 150 % of test concentration of 
artemether (20 µg/ml of artemether) and 
lumefantrine (120 µg/ml of lumefantrine) was 
satisfactory.  Recovery (% was between 
98.52 to 99.49% for artemether and 98.48 to 
99.73% for lumefantrine.   
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Table 1: Solubility of artemether and lumefantrine in various dissolution media (n = 3) 
 
Concentration  
(µg/ml, mean ± SD) 
Medium 
Artemether Lumefantrine 
Water 133 ± 4 Insoluble 
0.1N Hydrochloric acid 127 ± 5 Insoluble 
pH 4.5 Acetate buffer 130 ± 4 Insoluble 
pH 6.8 Phosphate buffer 119 ± 6 Insoluble 
1% w/v SLS in Water  4107 ± 12 16 ± 2 
1% w/v SLS in 0.1N Hydrochloric acid 2633 ± 21 216 ± 3 
1% w/v SLS in pH 4.5 Acetate buffer 3896 ± 11 238 ± 4 
1% w/v SLS in pH 6.8 Phosphate buffer 3511 ± 9 79 ± 10 
1% w/v BKC in Water  1230 ± 8 11 ± 2 
1% w/v BKC in 0.1N Hydrochloric acid 1055 ± 17 119 ± 3 
1% w/v BKC in pH 4.5 Acetate buffer 1246 ± 12 6 ± 1 
1% w/v BKC in pH 6.8 Phosphate buffer 1275 ± 11 3 ± 1 
1% w/v CTAB in Water  2544 ± 6 11 ± 2 
1% w/v CTAB in 0.1N Hydrochloric acid 2469 ± 16 175 ± 3 
1% w/v CTAB in pH 4.5 Acetate buffer 2555 ± 9 23 ± 2 
1% w/v CTAB in pH 6.8 Phosphate buffer 2589 ± 5 3 ± 1 
1% w/v Tween 80 in Water  643 ± 6 11 ± 1 
1% w/v Tween 80 in 0.1N Hydrochloric acid 639 ± 23 272 ± 5 
1% w/v Tween 80 in pH 4.5 Acetate buffer 641 ± 8 25 ± 2 
1% w/v Tween 80 in pH 6.8 Phosphate buffer 661 ± 6 7 ± 1 
1% w/v Myrj 52 in Water  536 ± 7 34 ± 2 
1% w/v Myrj 52 in 0.1N Hydrochloric acid 503 ± 19 813 ± 4 
1% w/v Myrj 52 in pH 4.5 Acetate buffer 524 ± 8 19 ± 2 
1% w/v Myrj 52 in pH 6.8 Phosphate buffer 528 ± 7 7 ± 1 
1% w/v Myrj 52 in 0.005N Hydrochloric acid 603 ± 4 463 ± 5 
1.5% w/v Myrj 52 in 0.005N Hydrochloric acid 897 ± 4 616 ± 4 





The intra-day and inter-day precision, 
compared in terms of %RSD, were close to 
each other indicating satisfactory level of 
precision of the method. %RSD for intra-day 
precision was 1.33 and 1.51 for artemether 
and 1.23 and 1.33 for lumefantrine on first 
and second day of analysis, respectively 
while%RSD for inter-day precision was 1.37 




The analytical method was linear for 
artemether and lumefantrine in the 
concentration range of 5 – 150 % of test 
concentration of the drugs. The test 
concentration of artemether was 20 µg/ml 
and that of lumefantrine 120 µg/ml . The 
regression analysis of the linearity data 
yielded correlation coefficient values above 
0.9990 for each drug (see Table 5). 
 
Specificity   
 
The specificity of the method was ascertained 
from the absence of peaks in the 
chromatogram of the dissolution medium at 
the retention times of artemether (Rt = 8.03 
min) and lumefantrine (Rt = 5.34 min) as well 
as from the purity angle values. For 
artemether, the purity angle was 0.849 and 
0.824 while the purity threshold was 1.269 
and 1.312 in standard and sample solutions, 
respectively. Similarly, for lumefantrine the 
purity angle was 1.656 and 1.632 while the 
purity threshold was 9.897 and 9.832 in  
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Table 2: Stability of artemether and lumefantrine  in various dissolution media (n = 3) 
 
Percent peak area reduction*  
Artemether Lumefantrine 
Medium 


















Water 0 0.61 1.12 1.96 Insoluble 
0.1N HCl 0 26.19 57.41 74.33 Insoluble 
pH 4.5 Acetate buffer 0 -0.26 2.03 0.79 Insoluble 
pH 6.8 Phosphate 
buffer 
0 
-0.36 1.15 1.31 
Insoluble 
1% w/v SLS in Water  0 -2.33 1.38 -0.86 0 0 0.00 0.04 
1% w/v SLS in 0.1N 
Hydrochloric acid 
0 
54.27 88.39 100 
0 0.01 0.01 -0.04 
1% w/v SLS in pH 4.5 
Acetate buffer 
0 
-0.14 0.98 0.35 
0 0.18 0.04 0.80 
1% w/v SLS in pH 6.8 
Phosphate buffer 
0 
0.43 -0.29 0.57 
0 3.30 7.02 9.10 
1% w/v BKC in Water  0 0.69 0.37 0.39 0 0.13 0.48 0.96 
1% w/v BKC in 0.1N 
Hydrochloric acid 
0 
1.73 12.16 17.74 
0 0.06 0.05 0.05 
1% w/v BKC in pH 4.5 
Acetate buffer 
0 
1.27 0.85 0.28 
0 -0.05 -0.01 0.01 
1% w/v BKC in pH 6.8 
Phosphate buffer 
0 
0.00 -0.14 0.28 
0 4.67 27.42 51.53 
1% w/v CTAB in 
Water  
0 
-0.86 0.13 -0.57 
0 -0.08 0.11 0.26 
1% w/v CTAB in 0.1N 
HCl 
0 
1.49 7.08 9.86 
0 0.03 0.34 0.45 
1% w/v CTAB in pH 
4.5 Acetate buffer 
0 
0.14 -0.14 0.95 
0 0.03 -0.14 0.30 
1% w/v CTAB in pH 
6.8 Phosphate buffer 
0 
0.14 0.42 0.42 
0 0.16 1.70 8.72 
1% w/v Tween 80 in 
Water  
0 
-0.15 0.45 0.75 
0 -0.07 0.41 0.50 
1% w/v Tween 80 in 
0.1N HCl 
0 
9.61 19.47 29.94 
0 1.50 2.76 6.24 
1% w/v Tween 80 in 
pH 4.5 Acetate buffer 
0 
0.42 -0.28 0.85 
0 0.01 0.02 0.55 
1% w/v Tween 80 in 
pH 6.8 Phosphate 
buffer 
0 
0.28 0.42 0.14 
0 0.02 0.19 0.61 
1% w/v Myrj 52 in 
Water  
0 
-0.56 0.56 0.14 
0 0.02 0.02 0.32 




9.60 20.47 31.81 
0 0.23 0.57 0.68 
1% w/v Myrj 52 in pH 
4.5 Acetate buffer 
0 
0.14 0.70 0.14 
0 0.28 0.31 0.58 
1% w/v Myrj 52 in pH 
6.8 Phosphate buffer 
0 
0.14 -0.28 0.28 
0 0.16 2.60 9.16 
1% w/v Myrj 52 in 
0.005N HCl 
0 
0.10 0.21 0.43 0 0.02 0.01 0.02 
1.5% w/v Myrj 52 in 
0.005N HCl 
0 
0.10 0.20 0.41 0 0.01 0.02 0.03 
2 % w/v Myrj 52 in 
0.005N HCl 
0 
0.12 0.22 0.44 0 0.02 0.03 0.05 
 
  SLS= Sodium lauryl sulphate    BKC= Benzalkonium chloride   CTAB= Cetyl trimethylammonium bromide 
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Table 3: Dissolution profile of reference product A in 0.005M HCl containing 1,1.5 and 2.%w/v of Myrj 52 (n 
= 24) 
 
Basket 100 RPM  Paddle 50 RPM  Paddle 75 RPM Paddle 100 RPM 
1% w/v Myrj 52 in 0.005M hydrochloric acid 
Time 
(min) 
 %Artemether release (mean ± SD) 
30 35.2 ± 2.6 39.6 ± 2.2 44.2 ± 3.2 53.4 ± 2.8 
60 47.5 ± 2.1 55.3 ± 2.9 64.6 ± 2.6 78.4 ± 2.1 
90 62.5 ± 1.8 73.2 ± 2.7 82.3 ± 1.9 95.4 ± 1.4 
120 74.7 ± 1.3 80.1 ± 2.3 89.4 ± 1.4 98.5 ± 1.1 
 % Lumefantrine release (mean ± SD) 
30 19.5 ± 1.3 21.4 ± 1.7 26.3 ± 2.1 35.4 ± 1.5 
60 35.3 ± 1.7 37.5 ± 2.6 44.4 ± 2.1 53.4 ± 2.2 
90 52.4 ± 2.5 56.6 ± 2.9 60.6 ± 2.2 65.4 ± 3.1 
120 62.9 ± 2.4 64.5 ± 2.3 68.3 ± 3.1 73.7 ± 2.9 
1.5% w/v Myrj 52 in 0.005M hydrochloric acid   
 % Artemether release (mean ± SD) 
30 37.2 ± 2.8 45.4 ± 3.1 54.4 ± 2.4 58.4 ± 2.9 
60 57.3 ± 3.1 65.1 ± 2.8 77.4 ± 2.5 84.6 ± 2.1 
90 74.6 ± 2.6 83.7 ± 1.9 94.4 ± 1.9 98.6 ± 1.7 
120 79.6 ± 2.1 88.6 ± 1.4 97.8 ± 1.4 100.8 ± 1.1 
 % Lumefantrine release (mean ± SD) 
30 22.3 ± 1.3 23.4 ± 1.1 36.8 ± 1.2 41.4 ± 1.8 
60 38.7 ± 3.3 44.4 ± 2.4 55.3 ± 2.8 60.4 ± 2.9 
90 55.4 ± 2.7 61.1 ± 3.1 66.4 ± 3.1 76.3 ± 2.7 
120 64.1 ± 3.3 67.2 ± 2.9 71.7 ± 2.8 84.3 ± 2.5 
2% w/v Myrj 52 in 0.005M hydrochloric acid  
 % Artemether release (mean ± SD) 
30 46.7 ± 2.7 55.8 ± 2.7 58.5 ± 3.2 69.4 ± 1.9 
60 65.2 ± 2.4 79.7 ± 2.2 84.9 ± 2.6 94.5 ± 0.9 
90 82.6 ± 1.7 92.7 ± 1.8 99.2 ± 1.5 100.1 ± 0.9 
120 86.5 ± 1.8 98.9 ± 1.3 100.2 ± 1.2 100.8 ± 0.7 
 % Lumefantrine release (mean ± SD) 
30 34.4 ± 2.2 36.4 ± 1.5 40.3 ± 2.2 47.8 ± 2.2 
60 53.4 ± 2.7 54.3 ± 2.2 59.8 ± 2.6 68.5 ± 2.0 
90 62.7 ± 2.7 64.4 ± 2.6 75.7 ± 2.6 93.4 ± 1.2 
120 67.6 ± 2.5 69.3 ± 2.3 83.4 ± 1.9 100.7 ± 1.1 
 
standard and sample solution, respectively. 
The purity angle value, being less than the 
purity threshold value, indicates that the 
peaks are spectrally pure in standard and 
sample solutions.   
 
Filter validation  
 
The filtration procedure for artemether and 
lumefantrine standard and sample solutions 
was evaluated using three different types of 
filters, namely, 0.45µ mdi nylon filter (A), 
0.45µ Whatman PTFE (B) filter and No. 42 
Whatman filter paper (C).  
The centrifuged solutions of the standard and 
sample were compared with the filtered 
solutions in terms of % recovery. The 
percentage peak area difference between the 
centrifuged solutions and solutions filtered 
through filters A, B and C was less than 1 % 
indicating that loss during filtration is within 
the acceptable limits. 
 
Stability of solution 
 
The stability of standard and sample 
solutions was studied for 24 h at room 
temperature. The standard and sample 
solutions were stable in 2 %w/v Myrj 52 in  
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Table 4: Dissolution profile of reference products A, B, C and test product in 2% w/v Myrj 52  in 0.005M 
















: About 80 
N) 
Test Product  
T-2 
(Hardness: 
About 40 N) 










 % Artemether release (mean ± SD) 
15 
58.3 ± 2.2 66.2 ± 2.3 
72.3 ± 
3.6 
46.2 ± 2.4 67.6 ± 2.9 33.4 ± 3.1 54.7 ± 3.4 
30 69.4 ± 1.9 76.4 ± 2.1 85.4 ± 
2.9 
58.9 ± 2.8 76.4 ± 2.4 49.5 ± 3.4 65.9 ± 3.1 
60 94.5 ± 0.9 95.1 ± 1.9 98.4 ± 
1.4 
 71.4 ± 1.9 90.3 ± 1.7  59.6 ± 2.7 81.7 ± 2.8 
90 100.1 ± 0.9 99.8 ± 1.1 100.1 ± 
1.1 
79.5 ± 1.5 100.5 ± 1.2 64.8 ± 2.9 89.8 ± 2.7 
120 100.8 ± 0.7 100.5 ± 0.9 101.3 ± 
0.8 
88.3 ± 1.7 100.5 ± 0.9 74.7 ± 2.4 98.5 ± 1.5 
f1 (Difference factor) 6.98  15.26  18.62  9.23  33.35  9.37  
f2 (Similarity factor) 60.43  45.12  39.01  57.09  26.98  53.15  
 % Lumefantrine release (mean ± SD) 
15 38.7 ± 1.8 
29.2 ± 1.2 
37.4 ± 
1.6 
23.4 ± 1.3 30.1 ± 3.1 17.8 ± 2.1 26.3 ± 2.9 
30 47.8 ± 2.2 46.3 ± 1.8 59.3 ± 
2.4 
35.7 ± 1.8 44.9 ± 2.8 26.2 ± 2.6 39.4 ± 3.1 
60 68.5 ± 2.0 72.1 ± 2.1 82.1 ± 
2.8 
51.9 ± 2.9 74.3 ± 2.4 39.7 ± 2.8 67.6 ± 2.9 
90 93.4 ± 1.2 87.4 ± 2.8 96.4 ± 
1.1 
69.4 ± 2.5 92.7 ± 2.0 55.7 ± 2.9 83.7 ± 2.5 
120 100.7 ± 1.1 96.3 ± 2.6 100.2 ± 
0.9 
78.7 ± 2.7 99.8 ± 1.2 65.9 ± 3.0 92.4 ± 1.9 
f1 (Difference factor) 8.29  11.84  25.78  7.25  41.19  11.37  




0.005M hydrochloric acid for a minimum 




The robustness of the method was evaluated 
by the varying chromatographic conditions of  
wavelength, flow rate, pH and composition of 
mobile phase of the analytical method.   As 
per the standard test method, the wavelength 
was 216 nm, flow rate 1.0ml/min, pH of 
mobile phase 3.0 and composition of mobile 
phase 20:80 buffer:acetonitrile. To evaluate 
the robustness of the method, the 
chromatograms were recorded with detection 
wavelengths of 213 nm and 219nm, flow rate 
of 0.8 ml/minute and 1.2 ml/minute, mobile 
phase pH of 2.8 and 3.2, and mobile phase 
composition of 22 : 78 and 18 : 82 v/v of 
buffer : acetonitrile.  The results of the 
chromatographic test under varied conditions 
indicated that the accuracy and precision are 
within the specified limits of 98 - 102 % for 
accuracy and %RSD of ≤ 2.0 for precision. 
No significant change was observed in 
system suitability parameters such as 
resolution, tailing factor, number of theoretical 





The sink condition for artemether (a minimum 
solubility of 60 µg/ml) may be achieved in all 
the dissolution media listed in Table 1 where-  
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Table 5: Linearity of response of artemether and lumefantrine 
 
Artemether Lumefantrine  








5 1.02 3078 6.03 1691399 
10 2.05 6187 12.05 3349978 
25 5.03 15781 30.07 8464426 
50 10.07 30993 60.11 16760389 
75 15.06 45454 90.06 25010957 
100 20.11 60697 120.04 33369990 
125 25.08 75497 150.12 42557238 
150 30.12 90809 180.04 50499341 
Slope 3004.7 281157 
Intercept 295.32 79052 





as the sink condition for lumefantrine (a 
minimum solubility of 360 µg/ml) may be 
achieved only in HCl containing more than 1 
%w/v of Myrj 52. Lumefantrine is practically 
insoluble in 0.1M HCl, pH 4.5 acetate buffer, 
pH 6.8 phosphate buffer and in water. 
Addition of a solubilising agent to these 
media resulted in various levels of solubility 
of lumefantrine in these media. Although the 
solubility of lumefantrine in HCl containing 
Myrj 52 was satisfactory, it was observed that 
the stability of lumefantrine in HCl in the 
presence of Myrj 52 increased as the molarity 
of HCl decreased.  On this basis, the 
dissolution medium of 1 %w/v of Myrj 52 in 
0.005M HCl was stable and provided sink 
conditions for artemether and lumefantrine. 
 
To verify the suitability of 1 %w/v of Myrj 52 in 
0.005M HCl as dissolution medium, 
dissolution release from reference product A 
was checked in three different dissolution 
media of 1, 1.5 and 2 %w/v Myrj 52 in 
0.005M HCl. The test was performed with a 
volume of 1000ml of each dissolution 
medium using USP dissolution apparatus 
type 1 (basket) and type 2 (paddle) with 
different rates of stirring. At a stirring rate of 
100 rpm of paddle, the release of artemether 
was above 90 % in all the three media but the 
release of lumefantrine was above 90 % only 
in 2 %w/v of Myrj 52 in 0.005M HCl. 
Lumefantrine release was about 73 % in 1 
%w/v of Myrj 52 in 0.005M HCl and 84 % in 
1.5 %w/v of Myrj 52 in 0.005N HCl.  
 
The results obtained show that the medium of 
2 %w/v Myrj 52 in 0.005M HCl with a stirring 
rate of 100 rpm for paddle was able to 
release 100.8 and 100.7 % of artemether and 
lumefantrine, respectively, from reference 
product A in 120 min. 
 
Therefore, this dissolution medium using 
paddle at 100 rpm for 120 minutes was 
selected for the dissolution test. The 
discriminating power of the selected method 
was verified by analyzing the three reference 
products (A, B and C), two in-house prepared 
test products with different hardness and in-
house test products exposed to 40 °C/75 % 
RH conditions for 15 days in an open dish. 
The dissolution results presented show that 
the proposed dissolution test has satisfactory 
discriminating power to distinguish the 
release profiles of the different reference 
products, the in-house products of different 
hardness and the in-house products which 
were exposed to heat and humidity.  Mann-
Whitney U test was applied to the data to find 
out whether each group of dissolution release 
values at a particular time point is different for 
different formulations. For example, the 
dissolution release values at 15 min of 
reference product A were  compared with the 
dissolution release values of test product 1 
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(T1)  using Mann-Whitney U test. Each of the 
z values obtained was > 1.96. The z value of 
1.96 is the critical value for a two-tailed test at 
the level of significance of 5 % (p = 0.05). 
Since the z values were > 1.96, it was 
inferred that the groups of values being 
compared are different from each other at p = 
0.05. This showed that the dissolution 
method is able to produce results which are 
different for different formulations at the 
various time points.  
 
Typical acceptance criteria for dissolution 
release of drugs from immediate release 
tablets is about 80 % of labeled amount in 45 
minutes [15]. Using 2 %w/v Myrj 52 in 
0.005M HCl with paddle at 100rpm,  95 % of 
artemether was released in 60 min from each 
of the reference products (A, B and C) 
whereas above 95 % of lumefantrine was 
released only around 120 min. Hence, with 2 
%w/v Myrj 52 in 0.005M HCl  as dissolution 
medium and with a stirring rate of 100 rpm 
with paddle, the suggested dissolution 
release acceptance limit would not be less 
than 85 % of artemether in 60 min and not 
less than 85 % of lumefantrine in 120 min. A 
single time point of not less than 85 % 
release of each drug in 120 min may be 
considered for quality control test.  However, 
the in-house limit for a particular tablet 
formulation of artemether and lumefantrine 
ought to be fixed on the basis of its 
dissolution performance using the developed 
method.  
 
The HPLC method used for the determination 
of dissolution release of artemether and 
lumefantrine from tablets were validated in 
terms of accuracy, precision, linearity, 
specificity, filter validation, solution stability 
and robustness. The results of validation 
showed that all the validation parameters are 
satisfactory. The peak areas of artemether 
and lumifantrine peaks were linear with 
respect to concentration. The correlation 
coefficient values of 0.9999 indicate excellent 
correlation between response (peak area) 




The proposed dissolution test method for 
artemether and lumefantrine in tablets 
provides sink condition and is able to 
satisfactorily discriminate drug release 
between formulations differing in terms of 
hardness, exposure to heat and moisture and 
composition of excipients. The analysis was 
carried out by a HPLC method which was 
validated. Hence the proposed dissolution 
method may be used as a single test method 
for the routine dissolution testing of tablets 
containing artemether and lumefantrine.  
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